ProCE Banner Activity

我为什么对长效抗逆转录病毒疗法感到兴奋,我为什么认为它会保留下来!

Conference Coverage
Clinical Thought
长效可注射抗逆转录病毒疗法已在加拿大的诊所使用,预计不久将在世界其他地区上市。即将推出的这一新选择和其他长效策略将如何影响我们的人类免疫缺陷病毒患者的临床护理,以及对英国患者和医疗服务提供者的经验有何具体影响?这是我的看法。

Released: May 05, 2020

Expiration: May 04, 2021

Share

Faculty

Chloe Orkin

Chloe Orkin, MBChB, FRCP, MD

Professor of Infection and Inequities – Queen Mary University of London
Dean for Healthcare Transformation – Queen Mary University of London
Honorary Consultant Physician – Barts Health NHS Trust
London, United Kingdom

Provided by

Provided by University of South Florida
ProCE Banner

Supporters

这项活动得到了Gilead Sciences;Merck & Co., Inc. 和 ViiV Healthcare 教育资金的支持。

Gilead

Merck & Co., Inc.

ViiV Healthcare

Faculty Disclosure

Primary Author

Chloe Orkin, MBChB, FRCP, MD

Professor of Infection and Inequities – Queen Mary University of London
Dean for Healthcare Transformation – Queen Mary University of London
Honorary Consultant Physician – Barts Health NHS Trust
London, United Kingdom

Chloe Orkin, MBChB, FRCP, MD 透露她曾在 Gilead Sciences、GlaxoSmithKline、Janssen、MSD 和 ViiV Healthcare 的咨询委员会/小组或发言人办公室任职,并已获得这些公司的研究支持资金。